Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: Effect on survival

Archives of Surgery

Volumn 145, Issue 12, 2010, Pages 1177-1183

  Nicolini, Andrea ^a,d   Ferrari, Paola ^a   Duffy, Michael J ^b,d   Antonelli, Alessandro ^a   Rossi, Giuseppe ^c   Metelli, Maria Rita ^a   Fulceri, Franca ^a   Anselmi, Loretta ^a   Conte, Massimo ^a   Berti, Piero ^a   Miccoli, Paolo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c CNR   (Italy)

^d Focus Group on Gastrointestinal Cancer   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ABDOMEN; ABDOMINAL ULTRASONOGRAPHY; ADULT; AGED; ARTICLE; CANCER RECURRENCE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; ECHOGRAPHY; FOLLOW UP; HUMAN; ITALY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; METASTASIS; METASTASIS RESECTION; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SERUM; THORAX RADIOGRAPHY; WHOLE BODY PET;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-19-9 ANTIGEN; COHORT STUDIES; COLECTOMY; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; REOPERATION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TISSUE POLYPEPTIDE ANTIGEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, DOPPLER;

EID: 78650798978     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2010.251     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
2. Mitry E, Bouvier AM, Esteve J, Faivre J. Improvement in colorectal cancer survival: a population-based study. Eur J Cancer. 2005;41(15):2297-2303. (Pubitemid 41415606)
3. Van Cutsem E, Costa F. Progress in the adjuvant treatment of colon cancer: has it influenced clinical practice? JAMA. 2005;294(21):2758-2760.
4. Rodríguez-Moranta F, Saló J, Arcusa A, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2006;24(3):386-393.
5. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15(3):938-946.
6. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990; 77(11):1241-1246.
7. Dahabre J, Vasilaki M, Stathopoulos GP, et al. Surgical management in lung metastases from colorectal cancer. Anticancer Res. 2007;27(6C):4387-4390.
8. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309-321.
9. Kanemitsu Y, Kato T, Hirai T, Yasui K. Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg. 2004;91(1):112-120.
10. Desch CE, Benson AB III, Somerfield MR, et al; American Society of Clinical Oncology. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005;23(33):8512-8519.
11. Sjövall A, Granath F, Cedermark B, Glimelius B, Holm T. Loco-regional recurrence from colon cancer: a population-based study. Ann Surg Oncol. 2007; 14(2):432-440.
12. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2007;(1):CD002200.
13. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002;324(7341):813.
14. Johnson FE, Virgo KS, Fossati R. Follow-up for patients with colorectal cancer after curative-intent primary treatment. J Clin Oncol. 2004;22(8):1363-1365. (Pubitemid 41103616)
15. Meyerhardt JA, Mayer RJ. Follow-up strategies after curative resection of colorectal cancer. Semin Oncol. 2003;30(3):349-360.
16. Chau I, Allen MJ, Cunningham D, et al. The value of routine serum carcinoembryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol. 2004; 22(8):1420-1429.
17. Locker GY, Hamilton S, Harris J, et al; ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313-5327.
18. Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg. 1998;228(1): 59-63.
19. Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum. 1998;41(9):1127-1133.
20. Arnaud JP, Koehl C, Adloff M. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum. 1980;23(3):141-144.
21. Mäkelä JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer: results of a prospective randomized trial. Arch Surg. 1995; 130(10):1062-1067.
22. Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg KG. Follow-up after curative surgery for colorectal carcinoma: randomized comparison with no follow-up. Dis Colon Rectum. 1995;38(6):619-626.
23. Kjeldsen BJ, Kronborg O, Fenger C, Jørgensen OD. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg. 1997; 84(5):666-669.
24. Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology. 1998;114(1):7-14. (Pubitemid 28020948)
25. Secco GB, Fardelli R, Gianquinto D, et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol. 2002;28(4):418-423.
26. Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg. 1954;139(6):846-852.
27. Nicolini A, Caciagli M, Zampieri F, et al. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the diagnosis of primary colorectal cancer and at its relapse. Cancer Detect Prev. 1995;19(2):183-195.
28. Nicolini A, Carpi A. Postoperative follow-up of breast cancer patients: overview and progress in the use of tumor markers. Tumour Biol. 2000;21(4):235-248.
29. Nicolini A, Ferrari P, Sagripanti A, Carpi A. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br J Cancer. 1999;79(9-10):1443-1447.
30. Nicolini A, Carpi A, Ferrari P, et al. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. Br J Cancer. 2000; 83(11):1412-1417.
31. Nicolini A, Colombini C, Luciani L, Carpi A, Giuliani L. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer. 1991;64(1):154-158.
32. Nicolini A, Carpi A, Ferrari P, Pieri L. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations. Tumour Biol. 2003;24(6):275-280.
33. Pfister DG, Benson AB III, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med. 2004;350 (23):2375-2382.
34. Figueredo A, Rumble RB, Maroun J, et al; Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003;3:26.
35. Anthony T, Simmang C, Hyman N, et al; Standards Practice Task Force, The American Society of Colon and Rectal Surgeons. Practice parameters for the surveillance and follow-up of patients with colon and rectal cancer. Dis Colon Rectum. 2004;47(6):807-817.
36. Virgo KS, Vernava AM, Longo WE, McKirgan LW, Johnson FE. Cost of patient follow-up after potentially curative colorectal cancer treatment. JAMA. 1995; 273(23):1837-1841.
37. Loprinzi CL, Hayes D, Smith T. Doc, shouldn't we be getting some tests? J Clin Oncol. 2000;18(11):2345-2348.
38. Mitchell EP. Role of carcinoembryonic antigen in the management of advanced colorectal cancer. Semin Oncol. 1998;25(5)(suppl 11):12-20.
39. Mann CD, Metcalfe MS, Neal CP, Rees Y, Dennison AR, Berry DP. Role of ultrasonography in the detection of resectable recurrence after hepatectomy for colorectal liver metastases. Br J Surg. 2007;94(11):1403-1407.
40. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000; 41(7):1177-1189.
41. 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer. 2008;98(5):875-880.
42. 18F-FDG PET in oncology. J Nucl Med. 2008;49(3):480-508.
43. Mauchley DC, Lynge DC, Langdale LA, Stelzner MG, Mock CN, Billingsley KG. Clinical utility and cost-effectiveness of routine preoperative computed tomography scanning in patients with colon cancer. Am J Surg. 2005;189(5):512-517.
44. Kjeldsen BJ, Kronborg O, Fenger C, Jørgensen OD. The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. Int J Colorectal Dis. 1997;12(6):329-334.
45. Barlow AD, Nakas A, Pattenden C, et al. Surgical treatment of combined hepatic and pulmonary colorectal cancer metastases. Eur J Surg Oncol. 2009;35(3): 307-312.
46. Kim AW, Faber LP, Warren WH, et al. Repeat pulmonary resection for metachronous colorectal carcinoma is beneficial. Surgery. 2008;144(4):712-718.
47. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24 (31):4976-4982.
48. Moriya Y. Treatment strategy for locally recurrent rectal cancer. Jpn J Clin Oncol. 2006;36(3):127-131.